08:00 , Dec 3, 2007 |  BC Week In Review  |  Company News

Harvard University endocrine, metabolic, cardiovascular news

The university spun out Syndexa Pharmaceuticals Corp. to develop compounds that target molecular mechanisms linking chronic inflammation to metabolic and other diseases, including Type II diabetes and atherosclerosis. The newco received an exclusive, worldwide license...
08:00 , Dec 11, 2006 |  BC Week In Review  |  Company News

PanGenetics management update

PanGenetics B.V. , Utrecht, the Netherlands   Business: Autoimmune, Cancer, Antibodies   Hired: Geoff Race as CFO, formerly CEO of CareX S.A. ; and Arnoud Dijkstra as SVP of business development, formerly director of business...
08:00 , Dec 11, 2006 |  BioCentury  |  Strategy

Antibody plucking

The raison d'etre behind PanGenetics B.V. is to arbitrage the value differential between preclinical antibodies and antibodies with human proof-of-principle data. With three in-house MAbs and two that it has in-licensed in the past two...
07:00 , May 29, 2006 |  BC Week In Review  |  Company News

CareX, 7TM deal

7TM acquired CareX for an undisclosed amount of stock. The deal adds CareX’s cannabinoid CB1 receptor antagonists, which are in lead optimization, to 7TM’s obesity pipeline. The Danish company’s TM30338 , a neuropeptide Y (NPY)...
07:00 , May 29, 2006 |  BioCentury  |  Strategy

Going for aggregation

Rather than close up shop or attempt to rebuild CareX S.A. after failures in the metabolic disease company's preclinical nuclear receptor pipeline, the board opted for an all stock acquisition by private metabolic company 7TM...
00:46 , May 25, 2006 |  BC Extra  |  Company News

7TM acquires CareX

7TM (Copenhagen, Denmark) acquired fellow metabolic company CareX (Strasbourg, France) for an undisclosed amount of stock. The deal adds CareX's cannabinoid CB1 receptor antagonists, which are in lead optimization, to 7TM's obesity pipeline. The Danish...
03:44 , Mar 1, 2005 |  BC Extra  |  Financial News

Index closes EUR 300M fund

Index Ventures raised EUR 300 million ($392 million) for its fourth fund, Index Ventures III. Investors included Adams Street; Alpinvest; BP Pension Fund; Horsley Bridge; HarbourVest; LGT Capital; Partners Group; and Schroders. Over the next...
08:00 , Jan 3, 2005 |  BioCentury  |  Finance

Ebb & Flow

It's only rational that investors in a private company want a stepup when the company goes public. Indeed, anti-dilution provisions typically are attached to the preferred shares that are issued in venture rounds. But most...
08:00 , Dec 23, 2004 |  BC Extra  |  Financial News

Hosang joins BioMedinvestor

Switzerland's BioMedinvest hired Markus Hosang as managing partner of BioMedinvestor, the VC firm's investment management arm. Hosang previously was a venture partner in MPM Capital's office in Germany. BioMedinvest's investments include cancer and autoimmune company...
07:00 , Jun 14, 2004 |  BioCentury  |  Product Development

PPAR pipeline

PPAR pipeline Company Compound MOA Status Milestone Bristol-Myers/Merck Muraglitazar (A) PPAR gamma and alpha agonist Ph III Submit NDA in 9-12 mos AstraZeneca Galida tesaglitazar PPAR gamma and alpha agonist Ph III Submit NDA and...